Biotech Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alnylam Pharmaceuticals, Inc.
Pharmaceutical firm adopts rights agreement
August 10th, 2005
Alnylam Pharmaceuticals, Inc., (ALNY), an RNAi therapeutics company, announced that its board of directors has approved a rights agreement under which its stockholders will receive preferred stock purchase rights. The rights agreement, which is similar to plans adopted by many other public companies, is designed to protect the long-term value of the stockholders' investment and was not adopted in response to any current third-party attempt to acquire the company. One right will be distributed as a non-taxable dividend on each outstanding share of common stock as of July 26, 2005. The rights will automatically trade with the underlying common stock...
Source: Biotech Week (2005-08-10)
|
